2103 ORAL A Randomized, Double-Blind Phase 2 Study of the Oral Tyrosine Kinase Inhibitor (TKI) Axitinib (AG-013736; AG) in Combination with Docetaxel (DOC) Vs DOC Plus Placebo (PL) in First-Line Metastatic Breast Cancer (MBC)
European Journal of Cancer Supplements（2007）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要